WO2014082609A1 - C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof - Google Patents
C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof Download PDFInfo
- Publication number
- WO2014082609A1 WO2014082609A1 PCT/CZ2013/000156 CZ2013000156W WO2014082609A1 WO 2014082609 A1 WO2014082609 A1 WO 2014082609A1 CZ 2013000156 W CZ2013000156 W CZ 2013000156W WO 2014082609 A1 WO2014082609 A1 WO 2014082609A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- acid
- derivative
- water
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims description 72
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 97
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims abstract description 88
- 229940099552 hyaluronan Drugs 0.000 claims abstract description 52
- 239000000126 substance Substances 0.000 claims abstract description 49
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 45
- RAFFVQBMVYYTQS-UHFFFAOYSA-N 2,4,6-trichlorobenzoic acid Chemical class OC(=O)C1=C(Cl)C=C(Cl)C=C1Cl RAFFVQBMVYYTQS-UHFFFAOYSA-N 0.000 claims abstract description 25
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 19
- 125000000524 functional group Chemical group 0.000 claims abstract description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 14
- 238000000527 sonication Methods 0.000 claims abstract description 12
- 239000013543 active substance Substances 0.000 claims abstract description 10
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 132
- 239000000243 solution Substances 0.000 claims description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 105
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 48
- 239000011541 reaction mixture Substances 0.000 claims description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 239000002253 acid Substances 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 27
- 229930012538 Paclitaxel Natural products 0.000 claims description 26
- 239000007864 aqueous solution Substances 0.000 claims description 26
- 229940088623 biologically active substance Drugs 0.000 claims description 26
- 229960001592 paclitaxel Drugs 0.000 claims description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 24
- 238000001556 precipitation Methods 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- 235000021313 oleic acid Nutrition 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 15
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- 230000002776 aggregation Effects 0.000 claims description 11
- 238000004220 aggregation Methods 0.000 claims description 11
- 239000008346 aqueous phase Substances 0.000 claims description 11
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 10
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 10
- 239000000010 aprotic solvent Substances 0.000 claims description 9
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000539 dimer Substances 0.000 claims description 8
- 239000004530 micro-emulsion Substances 0.000 claims description 8
- 239000007908 nanoemulsion Substances 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical group [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 239000000824 cytostatic agent Substances 0.000 claims description 6
- 230000001085 cytostatic effect Effects 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- ZCJLOOJRNPHKAV-ONEGZZNKSA-N (e)-3-(furan-2-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CO1 ZCJLOOJRNPHKAV-ONEGZZNKSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- KKMZQOIASVGJQE-UHFFFAOYSA-N 3-thiophen-2-ylprop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CS1 KKMZQOIASVGJQE-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 3
- 235000019395 ammonium persulphate Nutrition 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000007348 radical reaction Methods 0.000 claims description 3
- 239000001195 (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid Substances 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 238000007738 vacuum evaporation Methods 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 abstract description 15
- 230000035515 penetration Effects 0.000 abstract description 15
- 125000002252 acyl group Chemical group 0.000 abstract description 14
- 150000001735 carboxylic acids Chemical class 0.000 abstract description 11
- 238000005886 esterification reaction Methods 0.000 abstract description 10
- 239000000969 carrier Substances 0.000 abstract description 4
- 230000010399 physical interaction Effects 0.000 abstract description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 66
- 239000002244 precipitate Substances 0.000 description 50
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 33
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 30
- 150000008064 anhydrides Chemical class 0.000 description 30
- 239000000693 micelle Substances 0.000 description 27
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 26
- 239000008186 active pharmaceutical agent Substances 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 239000013557 residual solvent Substances 0.000 description 18
- 238000010908 decantation Methods 0.000 description 17
- 229920002385 Sodium hyaluronate Polymers 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 229940010747 sodium hyaluronate Drugs 0.000 description 16
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 16
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 13
- 229920001282 polysaccharide Polymers 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 229930003799 tocopherol Natural products 0.000 description 11
- 229960001295 tocopherol Drugs 0.000 description 11
- 239000011732 tocopherol Substances 0.000 description 11
- 235000010384 tocopherol Nutrition 0.000 description 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 11
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 10
- 239000005642 Oleic acid Substances 0.000 description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 229930003427 Vitamin E Natural products 0.000 description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 210000004400 mucous membrane Anatomy 0.000 description 9
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 229940046009 vitamin E Drugs 0.000 description 9
- 230000032050 esterification Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- -1 styryl pyridinium Chemical compound 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 4
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001249 flow field-flow fractionation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101100332755 Mus musculus Edar gene Proteins 0.000 description 2
- 240000003492 Neolamarckia cadamba Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100332756 Oryzias latipes edar gene Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 150000002889 oleic acids Chemical class 0.000 description 2
- 238000013021 overheating Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000001370 static light scattering Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000378 teratogenic Toxicity 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- TVZDIFXOIOIPJG-UHFFFAOYSA-N 2,3,4-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1Cl TVZDIFXOIOIPJG-UHFFFAOYSA-N 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000028654 Type IV pili-dependent aggregation Effects 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000021158 dinner Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 231100000110 immunotoxic Toxicity 0.000 description 1
- 230000002625 immunotoxic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 238000000707 layer-by-layer assembly Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005481 linolenic acid group Chemical group 0.000 description 1
- 125000005644 linolenyl group Chemical group 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Inorganic materials [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940033816 solvent red 27 Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/30—Sulfur-, selenium- or tellurium-containing compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/30—Sulfur-, selenium- or tellurium-containing compounds
- C08K2003/3045—Sulfates
Definitions
- the invention relates to a method of preparation hydrophobized hyaluronic acid and its use as carrying biologically active hydrophobic substances, wherein a biologically active substance is encapsulated into the nanomicelles of hydrophobized hyaluronan.
- the hydrophobization of hyaluronan is carried out through an esterification reaction of hyaluronan with long-chain carboxylic acids, the latter being activated by a halogenide derivative of 2,4,6-trichlorobenzoic acid or by another organic chloride of R3-CO-CI.
- water-soluble hydrophobized derivatives can form nanomicelles in which nonpolar substances can be bound by means of non-covalent physical interactions.
- the core of a nanomicelle is formed by hydrophobic acyl functional groups while the shell of a nanomicelle is formed by hyaluronic acid.
- the encapsulation of the substances into nanomicelles can be performed by means of the solvent exchange method or by means of sonication.
- Hyaluronic nanomicelles support the penetration of bound substances in topical applications and enable the bound substances to be transferred into the individual cells.
- the invention further relates to a method for preparing stabilized nanomicellar compositions.
- the nanomicelles obtained from hydrophobized hyaluronan derivatives are usable in cosmetic and pharmaceutical applications.
- Hyaluronic acid is an important polysaccharide consisting of two repeating units of P-( l ,3)-D-glucuronic acid and P-(l ,4)-N-acetyl-D-glucosamine. It is characterized by a high molecular weight ranging from 5. I 0 4 to 5.10 6 g.mof 1 which depends on the isolation method and on the initial material used.
- Hyaluronic acid, and particularly its sodium salt known as hyaluronan. is and essential constituent of connective tissues and of synovial joint fluid. Moreover it plays a signi ficant role in numerous biological processes, such as hydration, organization of proteoglycans, cellular differentiation, proliferation and angiogenesis. This polysaccharide, which is strongly hydrophilic, is water soluble in the form of salts within the entire pH scale.
- hyaluronic acid Due to the hydrophilic nature of its native form, hyaluronic acid cannot serve as an effective carrier for hydrophobic substances. For this reason, hydrophobic functional groups have to be linked to a polymeric chain of hyaluronic acid. In case that such hydrophobic functional groups have sufficient quantities and lengths, an auto- aggregation process involving the same can be initiated resulting in the formation of hydrophobic domains within the structure of hyaluronan. Afterwards, small molecules of water insoluble substances can be linked to such domains by means of non-covalent bonds.
- the resulting structure is often referred to as polymeric nanomicelle in the literature, wherein the core of the micelle is hydrophobic, thus enabling the dissolution of small nonpolar molecules to take place, while the shell of the same is hydrophilic. thus enabling the polymeric micelle itself to be dissolved in an aqueous environment.
- a polymeric micelle which does not exceed 200 nm in size (diameter), can be referred to as nanomicelle.
- Carrier systems formed by polymeric micelles on the basis of modified hyaluronic acid are known from conjugates of hyaluronan with alkylamines (Liu et al., 201 1 ) and folic acid. Nevertheless, the presence of highly toxic and teratogenic formamide is deemed to be essential for the preparation of the above hyaluronan derivative.
- a similar method of preparation of polymeric m icelles was employed for obtaining redox- sensitive micelles (Li et al.. 201 1 ). It is obvious that such micellar systems are not usable in biological applications due to the presence of highly toxic reagents.
- the purpose of the latter was to prepare a carrier for genes.
- the use of sper ine for the above purpose is restricted due to its acute and subacute toxicity (Til. Falke, Prinsen & Willems, 1997).
- the critical micellar concentration of the formed polymeric micelles having 1 25-555 in diameter was determined to be higher than 0.04 mg.mL " 1 .
- the value of the critical m icellar concentration is too high and hence does not enable any extreme dilution of micellar system to be achieved (e.g.
- the micelles having the above mentioned size are not considered to be suitable candidates for the passive distribution of medicines within the human body because the size of a polymeric micelle is determinative for the ability of the same to reach a tumor location or infarct lesion through a disrupted venous wall.
- polymeric micelles having 20- 100 nm in diameter are preferred (Wang. Mongayt & Torchilin, 2005).
- the negative charge of the molecule may have a significant unfavourable influence on the interaction between cells and the respective carrier system (Wang, Mongayt & Torchilin, 2005).
- One of the lim iting factors for the injection application of the derivatives prepared in the above manner consists in their low solubility (Eenschooten. Guillaumie, Kontogeorgis, Stenby & Schwach-Abdellaoui, 201 0).
- Another disadvantage of such derivatives consists in the instability of the ester bonds during thermal sterilization processes, such as autoclaving ones.
- butyric esters of polysaccharides including a corresponding pharmaceutical composition is claimed in the patent EP 0941253.
- the claimed methodology of preparation enables only very low degrees of substitution to be achieved (3% max. ).
- the quantity of the hydrophobic substance, which is linked to the prepared derivatives by means of a non-covalent bond, is unfavourably influenced by such a low degree of substitution.
- the butyric esters of hyaluronan were further prepared in accordance w ith the patent WO 2005/092929 wherein, however, nonaqueous conditions. Consequently, the transformation of hyaluronan into a quaternary ammonium salt may be accompanied by the degradation of hyaluronan.
- Another drawback of the claimed derivatives consists in their conjugation with polymers, e.g. with polyethylene glycol, which are extraneous in relation to the human body and can cause inflammatory reactions or give rise cytotoxic degradation products when used for intravenous or topical applications.
- polymers e.g. with polyethylene glycol
- polyethylene glycol e.g. with polyethylene glycol
- repeated application of polymeric micelles, where polyethylene glycol formed the hydrophilic segment led to accelerated elimination of those micelles from the bloodstream due to the formation of anti-PEG IgM antibodies (Gong, Chen. Zheng. Wang & Wang. 2012).
- Paclitaxel was successfully incorporated into the micelles of modified hyaluronan by means of poly lactic-co-glycolic acid (PLGA) (Kim, Lee, Jang & Park, 2009).
- the incorporation was carried out with the use of a dialythic method wherein both the polymer and the respective bound substance were dissolved in DMSO and the resulting solution was dialyzed against H 2 O. In the latter case, the bonding capacity of prepared polymeric m icelles of 4.5% by weight was obtained.
- the main disadvantage of such carrier systems consists in the presence of PLGA polymers, which are extraneous with respect to the human body and may not represent a fully biodegradable system. Another disadvantage consists in the presence of residual DMSO in the final products.
- Acid anhydrides can be substituted with other acid derivatives which are usable for the esterification of hvaiuronan.
- the patent WO 2010/105582 claim the method of activation of carboxylic acids by means of ethylchloroformiate in non-aqueous conditions, wherein O-acyl-O'-alkyl carbonates are formed which are subsequently usable for the esterification of hvaiuronan.
- the disadvantage of such activation consists in the formation of toxic and potentially explosive gases.
- a similar method of activation with ethylchloroformiate is disclosed in the patents U .S. 3,720,662 and CZ 20060605.
- the subject matter of the present invention is the synthesis of a hydrophobized derivative of hyaluronic acid and the application of said derivative in the form of a polymeric carrier for biologically active hydrophobic substances in aqueous environment, wherein the native character and the biological activity of the bound substances should remain unchanged.
- the hydrophobization of hyaluronan with long-chain aliphatic esters is based on the direct activation of long-chain carboxylic acids accompanied with the formation of an anhydride of 2,4,6-trichlorobenzoic acid (Scheme 1 ).
- the resulting anhydride reacts with hyaluronic acid to form an acylated derivative of hyaluronic acid.
- the principal advantage of said activation consists in the possibility of the direct application of aliphatic carboxylic acids. Unlike the similar hydrophobizing reactions of hyaluronan, which constitute the prior art, the presented modification does it require any commercially available anhydride to be used.
- Another advantage of the presented activation consists in the fact that the respective reaction can take place under moderate conditions (from the room temperature up to 50°C) and has a short duration. Furthermore, the presented activation requires, unlike the method disclosed in the patent application WO 2010/105582, neither an excessive quantity of aliphatic acids nor special anhydrous conditions.
- the activating reagent is stable and. unlike ethylchloroformiate, does not cause the production of toxic or explosive gases when used in the reaction.
- Another advantage of the presented activating reagent consists in that the reagent does not form any reaction by-products and does not induce cross-linking reactions.
- OK-TCB-A anhydride of organic acid and 2,4,6-trichlorobenzoic acid
- the invention relates to the use of hydrophobized hyaluronic acid for preparation of nanomicellar systems and to the application of the substances bound in the nanomicelles of hyaluronic acid for the treatment of skin, hair and mucous membranes, other topical applications being also possible.
- the encapsulated biologically active substances are bound in the nanomicelles of hyaluronan by non-covalent physical interactions with hydrophobic functional groups of the polymeric carrier.
- hydrophobic functional groups of the polymeric carrier When encapsulated in the above manner, such substances effectively penetrate into the superficial skin layer (epidermis), into the entire structure of hairs and into the epithelium of mucous membranes.
- One of the advantages consists in that the penetration depth of the active substances bound in the nanomicelles is greater that that of the same substances when the -latter are directly dissolved in nonpolar solvents.
- the nanomicellar conjugates of hyaiuronan have unexpectedly exhibited a 3-fold to 10-fold lower critical micellar concentration and, simultaneously, a relatively high stability in salty and aqueous environments.
- Such a very low value of the critical micellar concentration is particularly advantageous in connection with possible intravenous applications of hyaiuronan micelles.
- the high stability of hyaiuronan micelles may be advantageous in connection with the lyophilisation of various materials because the desired encapsulation can be preserved without adding any lyoprotectant to the solution before freezing.
- Another advantage of the claimed hydrophobized derivatives of hyaiuronan is related to the absence of synthetic polymers (PLGA, PEG. etc.) and copolymers which are - otherwise often necessary for the fonnation of nanomicelles and which can trigger the creation of antibodies when administered repeatedly (Gong. Chen, Wang & Wang).
- nanomicelles is not based on a modified hyaiuronan having an increased total negative charge, and thus the interaction between the carrier system with cells is not unfavourably influenced by such charge.
- nanomicellar structures particularly those containing longer acyl chains linked to hyaiuronan. may form a gel phase in an aqueous environment.
- a gel phase may be advantageously used in certain applications requiring and increased viscosity of the respective carrier system.
- the dimensions of the prepared nanomicellar systems mostly range between 20 and 22.
- hyaiuronan micelles Another advantage of the hyaiuronan micelles is related to the transfer of bound substances from the hydrophobic domains of a nanomicelle into a cell.
- the innovated encapsulating method is based on the preparation of a mixture of hyaluronan dissolved in water and a biologically active substance dissolved in an organic solvent, followed by the energetic disruption of the hydration envelope of hyaluronan and subsequent removal of the solvent from the solution.
- the above method is not based on the solubility of polymers in an organic solvent and hence does not require the native character of hyaluronic acid to be suppressed and the polymeric chain to be largely modified, particularly in the location of the important carboxylic groups which enable hyaluronan to be recognized by cellular receptors.
- a preferred organic solvents is that having a lower boiling point than water.
- the bonding capacity of hyaluronan nanomicelles is markedly increased by the complete evaporation of the residual aqueous phase with the subsequent rehydration of nanomicelles. An unbound biologically active substance can be eliminated in a filtration process and the resulting - nanomicelles can be directly lyophilized and stored in dry state until the time of the subsequent rehydration.
- the invention relates to a C 6 -Cis-acylated derivative of hyaluronic acid according to the general formula (1):
- x is an integer ranging between 5 and 17 and y is an integer ranging between 1 1 and 35 and C x H y is a linear or branched, saturated or unsaturated C 5 -C
- the Co-C iij-acylated derivative is an oleyl derivative which means that R represents H + or Na + and R 1 represents CH 3 in the formula (I).
- the invention relates to the method of preparation of the above derivative of hyaluronic acid, wherein hyaluronic acid reacts with C(,-C i 8-carboxylic acid activated with a chloride of 2.4,6-trichlorobenzoic acid or activated with an organic chloride of R3-CO-CI under presence of a base and a catalyst in a m ixture of water and a water-miscible aprotic solvent, where R 3 is an aliphatic or branched Ci-C 3 o-alkyl occasionally containing heteroaromatic or aromatic functional groups.
- An exemplary heteroaromatic functional group may be pyridine along with its derivatives (e.g. according to the formula (i)), an exemplary aromatic functional group may benzene along with its halogen derivatives (e.g. according to the formula (ii)).
- Hyaluronic acid may assume the free acidic form or the form of a pharmaceutically acceptable salt, such as a Na. , Ca, Mg, Zn, or Li salt, and have a molecular weight ranging preferably between 5x 10 J g/mol and 1 ,6x 0 6 g/mol. more preferably between 15xl0 J g/mol and 250xl O J g/mol, and most preferably between 15xl 0 3 and 50xl 0 3 g/mol.
- a pharmaceutically acceptable salt such as a Na. , Ca, Mg, Zn, or Li salt
- the method of preparation according to the invention consists in that hyaluronic acid is dissolved in a mixture of water and a water-miscible aprotic solvent, the latter being a polar organic solvent, the water content being in the range between 10 and 99% by volume, preferably 50% by volume.
- the water-miscible aprotic solvent may be, for example, dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), acetone, acetonitrile or isopropanol (LPA).
- the reaction mixture contains an R' 3 N base, w herein R' is a linear or branched C n H m hydrocarbon chain, wherein n is an integer ranging between 1 and 4 and m is an integer ranging between 3 and 9. e.g. triethylamine, in the amount of 0.01 to 20 equivalents, preferably 6 equivalents, relative to a dimer of hyaluronic acid, and the catalyst is selected from the group comprising substituted pyridinines, such as dimethylaminopyridine, in the amount of 0.01 to 1 equivalent, preferably 0.05 equivalent, relative to a dimer of hyaluronic acid.
- R' is a linear or branched C n H m hydrocarbon chain, wherein n is an integer ranging between 1 and 4 and m is an integer ranging between 3 and 9.
- triethylamine in the amount of 0.01 to 20 equivalents, preferably 6 equivalents, relative to a dimer of hyaluronic acid
- the catalyst is
- the activation of Q-C is-carboxy ic acid is performed in a polar organic solvent under the presence of a base and of 2.4.6-trichlorobenzoic acid or its derivatives or under the presence of a base and an organic chloride and subsequently the mixture containing activated C6-Ci 8 -carboxylic acid is added to hyaluronic acid, which was dissolved in a mixture of water, an organic solvent, a base and a catalyst, the product of the resulting reaction being the derivative according to the general formula (I).
- Said C 6 -C i 8- carboxylic acid is selected from the group containing caproic, enanthic.
- caprylic, capric, palmitic, stearic, oleic, linoleic and linolenic acids ranges between 0.01 and 5 equivalents, preferably between 0.5 and 2 equivalents, relative to a dimer of hyaluronic acid.
- the activation of C6-Cis-carboxylic acid takes places for 5 to 120 minutes, preferably for 30 minutes, under the temperature between 20 and 60°C, preferably under the temperature of 25°C.
- the reaction of hyaluronic acid with activated C6-C ] 8 -carboxylic acid takes places for 1 to 24 hours, preferably for 2 to 3 hours, under the temperature between 20 and 60°C, preferably under the temperature of 25°C.
- the CVC is-acylated derivative of hyaluronic acid may be subsequently separated from the reaction mixture, washed, dried and lyophilized.
- the derivative may be separated from the reaction mixture by precipitation using NaCl and alcohol. Subsequently, the derivative may be washed with alcohol, particularly with isopropanol or ethanol.
- the invention relates to a nanomicellar composition on the basis of a Cfi-C is-acylated derivative of hyaluronic acid according to the general formula (I), which composition contains nanomicelles which comprise a hydrophobic core formed by C 6 -C is-acyl groups linked to hyaluronic acid and a hydrophilic shell formed by hydrophilic functional groups of hyaluronic acid, one or more biologically active substances being physically bound in each nanomicelle.
- the composition further contains water and may also contain salts (e.g. 0.9% NaCl).
- the nanomicellar composition contains 0.3 to 50% by weight of a biologically active substance relative to the mass content of the C6-C i 8-acylated derivative of hyaluronic acid, the biologically active substance being selected from a group comprising pharmaceutically and cosmetically active substances, particularly vitamins, medicines, cytostatics, phytoextracts, phytocomplexes or phytoactive substances, mineral or vegetable oils, or a mixture thereof.
- a biologically active substance particularly vitamins, medicines, cytostatics, phytoextracts, phytocomplexes or phytoactive substances, mineral or vegetable oils, or a mixture thereof.
- the examples of applicable biologically active substances include, e.g., tocoferol. paclitaxel, phosphatidylcholine or coenzyme Q10.
- the composition contains a Cc-Cis-acylated derivative of hyaluronic acid in a concentration which is higher than its critical aggregation concentration.
- concentration of the C 6 -C ) 8 - acylated derivative of hyaluronic acid ranges between 0.0001 mg.mL " 1 and 30 mg.mL " ' . preferably between 1 and 20 mg.mL " ' , when the composition is in an aqueous solution.
- the biologically active substance is a mineral or vegetable oil contained in the amount of 0.05 to 40% by weight, preferably 1 to 20% by weight, relative to the mass content of the C6-Ci 8 -acylated derivative of hyaluronic acid.
- the composition contains a biologically active substance which is liquid and insoluble in water, said substance containing an additional biologically active substance dissolved therein.
- biologically active substance which is liquid and insoluble in water
- the additional biologically active substance may belong, e.g.. among pharmaceutically or cosmetically active substances, particularly vitamins, medicines, cytostatics, phytoextracts, phytocomplexes or phytoactive substances, or mixtures thereof.
- the nanomicellar composition according to the invention may assume the form of a solution, nanoemulsion, microemulsion, coacervate or gel.
- the invention further relates to the method of preparation of the nanomicellar composition as defined above, wherein the Cg-Cig-acylated derivative of hyaluronic acid according to the general formula (I) is dissolved in water, the biologically active substance is dissolved in an organic solvent, the resulting solutions are mixed together and afterwards the organic solvent is removed.
- the organic solvent may be a volatile chlorinated solvent, such as trichloromethane, or an alcohol, such as ethanol or isopropanol. and its removal may take place by vacuum evaporation. Subsequently the aqueous phase is dried and rehydrated and the resulting nanomicellar structures are filtered and finally lyophilized. Alternatively, the organic solvent may be removed by dialysis.
- the resulting nanomicellar structures are subsequently filtered and finally lyophilized.
- 8 -acylated derivative of hyaluronic acid according to the general formula (I) is dissolved in water and subsequently mixed together with a biologically active substance, which is liquid and insoluble in water, whereupon the resulting mixture is homogenized by sonication to form a microemulsion or nanoemulsion.
- the C6-C 18 -acylated derivative of hyaluronic acid according to the general formula (i) is dissolved in water and subsequently mixed together with a biologically active substance, which is liquid and insoluble in water and in which an additional biologically active substance is dissolved, whereupon the resulting mixture is homogenized by sonication to form a microemulsion or nanoemulsion.
- the invention relates to the use of the nanomicellar composition in pharmaceutical or cosmetic applications, preferably in topical application.
- a stabilized nanomicellar composition may be prepared.
- the method of preparation of such a stabilized nanomicellar composition consists in that C -C ]8 - acylated hyaluronan according to the general formula (II) is prepared:
- R represents H or Na
- one or more R members are represented by a linear C 6 - Cis-chain in at least one repeating unit, which linear chain can contain unsaturated bonds, and by 3-(2-thienyl)acrylic acid or by 3-(2-furyl)acrylic acid or by derivatives of said acids in another at least one repeating unit, whereupon a nanomicellar composition is prepared from the C 6 -Ci 8 -acylated hyaluronan according to the general formula (II), which composition is then stabilized in a cross-linking reaction.
- the stabilization is carried out in the following manner: first, the derivative according to the general formula (III) is prepared:
- hyaluronic acid is dissolved in water and afterwards a base (such as TEA) and a catalyst (DMAP); in a separate procedure, activated 3-(2-thienyl)acrylic acid or 3-(2- furyl)acrylic acid or a derivative of either acid is prepared, the activation taking place in a mixture of an organic solvent (e.g. THF) and a base (e.g. TEA) with the addition of an chloride of 2,4,6-trichlorobenzoic acid, and finally both mixtures are mixed together to form acrylated hyaiuronan according to the formula (III).
- a base such as TEA
- DMAP catalyst
- activated 3-(2-thienyl)acrylic acid or 3-(2- furyl)acrylic acid or a derivative of either acid is prepared, the activation taking place in a mixture of an organic solvent (e.g. THF) and a base (e.g. TEA) with the addition of an chloride of 2,4,6-trichloro
- activated Ce-C is- carboxylic acid is prepared for the acylation of said acrylated hyaiuronan according to the formula (III) in a manner, which is similar to that described above with reference to the method of preparation C6-C ⁇ -acylated hyaiuronan according to the general formula (I ), to form acylated hyaiuronan according to the formula (11).
- nanomicelles may be analogously prepared from the acylated hyaiuronan which has been prepared in the above manner. Such nanomicelles may be subsequently cross-linked in radical reactions, e.g. using ammonium peroxydisulfate. Such cross-linked hyaiuronan is not soluble in water.
- Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel.
- FIG. 7 Profile of the release of encapsulated oil red from the HAC6 carrier into PBS and into PBS containing 1% of added TWEEN 80. Concentration of HAC6 + oil red: 1 or 10 mg.mL "1 .
- FIG. 9 Penetration of encapsulated Nile red (NR) from hyaluronan nanomicelles HA(C6) and HA (C I O) vs. penetration of Nile red dissolved in oil and dispersed in water into skin, either Nile red sample having the same concentration.
- FIG. 10 Penetration of encapsulated Nile red (NR) from hyaluronan nanomicelles HA(C6) and HA (C I O) vs. penetration of Nile red dissolved in oil and dispersed in water into hair, either Nile red sample having the same concentration (the microscopic image shows a cross section of a hair strand).
- FIG. 1 Penetration of encapsulated Nile red (NR) from polymeric hyaluronan nanomicelles HA(C6) and HA (C I O) vs. penetration of Nile red dissolved in oil and dispersed in water into buccal mucous membrane, either Nile red sample having the same concentration.
- NR encapsulated Nile red
- equivalent refers to a dimer of hyaluronic acid. Unless otherwise specified, percentages are figured on a weight/weight basis.
- the molecular weight of the primary hyaluronic acid was determined by means of the SEC-MALLS method.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.25 g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMSO and DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the potpose of removing the residual solvents.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0,75 g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove acetonitrile and DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- octanoic acid (0.63 g, 4 eq.) was dissolved in 5 mL of acetonitrile and then TEA (1 .05 mL, 3 eq.) and 2,4,6-trichlorobenzoyl chloride (0.8 mL, 4 eq.) were added to the solution.
- TEA 1 .05 mL, 3 eq.
- 2,4,6-trichlorobenzoyl chloride 0.8 mL, 4 eq.
- the acylated derivative was isolated from the reaction mixture in the subsequent - precipitation process using the 4-fold of absolute isopropanol. After having undergone decantation. the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove acetonitrile and DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.25 g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently w ith absolute isopropanol in order to remove water from the derivative.
- the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0,25 g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove THF and DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- 0.5 g of sodium hyaluronate ( 1.25 mmol, 38 kDa) were dissolved in 20 mL of demineralized water. Afterwards, 10 mL of THF were gradually added. Then, TEA (0.52 mL. 3 eq.) and DMAP (8.0 mg, 0.05 eq.) were added to the solution. Simultaneously, palmitic acid (0.16 g, 0.5 eq.) was dissolved in 10 mL of THF and then TEA (0.52 mL, 3 eq.) and 2,4,6-trichlorobenzoyl chloride (0.098 mL, 0.5 eq.) were added to the solution.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.25 g of NaCl.
- the acylated derivative was isolated from the reaction m ixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- 0.5 g of sodium hyaluronate (1.25 mmol. 15 kDa) were dissolved in 10 mL of demineralized water. Afterwards. 5 mL of THF were gradually added. Then, TEA (0.52 mL. 3 eq.) and DMAP (8.0 mg, 0.05 eq.) were added to the solution. Simultaneously. stearic acid (0.71 1 g, 2 eq.) was dissolved in 5 mL of THF and then TEA (0.52 mL. 3 eq.) and 2,4.6-trichlorobenzoyl chloride (0.391 mL. 2 eq.) were added to the solution.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under the room temperature for 3 hours and subsequently the reaction mixture was being wanned up at 50°C for 1 hour. Afterwards. the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.25 g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol. ) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- 0.5 g of sodium hyaluronate (1.25 mmol, 1 5 kDa) were dissolved in 10 mL of demineralized water. Afterwards. 5 mL of THF were gradually added. Then, TEA (0.52 mL. 3 eq.) and DMAP ( 15.0 mg. 0.1 eq.) were added to the solution. Simultaneously, oleic acid (0.18 g, 0.5 eq.) was dissolved in 5 mL of THF and then TEA (0.52 mL, 3 eq.) and 2,4,6-trichlorobenzoyl chloride (0.098 mL, 0.5 eq.) were added to the solution.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.25 g of NaCl.
- the acyiated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently w ith absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- Example 10 Preparation of oleyl (C18:l) derivative of hyaluronic acid by means of the mixed anhydride of 2,4,6-trichlorobenzoic acid and oleic acid
- 0.5 g of sodium hyaluronate ( 1.25 mmol, 130 kDa) were dissolved in 5 mL of demineralized water. Afterwards, 3 mL of isopropanol were gradually added. Then. TEA (0.52 mL, 3 eq.) and DMAP ( 15.0 mg, 0.1 eq.) were added to the solution. Simultaneously, oleic acid (0.4 mL. 1 eq.) was dissolved in 5 mL of isopropanol and then TEA (0.52 mL, 3 eq.) and 2,4,6-trichlorobenzoyl chloride (0.195 mL. 1 eq.) were added to the solution.
- TEA 0.52 mL, 3 eq.
- 2,4,6-trichlorobenzoyl chloride (0.195 mL. 1 eq.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours.
- the reaction mixture was diluted with 5 mL of demineralized water containing the addition of subsequent precipitation process using the 4-tbld of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative.
- the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.50 g of NaCl.
- the acy ated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol. After having undergone decantation. the precipitate was repeatedly washed initially w ith the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents. DS 1 1 % (determined from NMR)
- 0.5 g of sodium hyaluronate (1.25 mmol, 130 kDa) were dissolved in 5 mL of demineralized water. Afterwards, 3 mL of THF were gradually added. Then, TEA (1.2 mL. 3 eq.) and DMAP ( 15.0 mg, 0.1 eq.) were added to the solution. Simultaneously, oleic acid (0.787 mL, 2 eq.) was dissolved in 10 mL of THF and then TEA (0.52 mL. 3 eq.) and 2,4,6-trichlorobenzoyl chloride (0.391 mL, 2 eq.) were added to the solution.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.25 g of NaCI.
- the acyiated derivative was isolated from the reaction mixture in the subsequent " precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- Example 13 Preparation of the linoleyl (CI 8:2) derivative of hyaluronic acid by means of the mixed anhydride of 2,4,6-trichlorobenzoic acid and linoleic acid
- 0.5 g of sodium hyaluronate ( 1.25 mmol, 15 kDa) were dissolved in 10 mL of demineralized water. Then. TEA (0.52 mL. 3 eq.) and DMAP (8 mg. 0.05 eq.) were added to the solution. Simultaneously, linoleic acid (0,77 mL, 2 eq.) was dissolved in 3 mL of THF and then TEA ( 1 ,2 mL, 7 eq.) and 2,4,6-trichlorobenzoyl chloride (0.391 mL, 2 eq.) were added to the solution.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours.
- Aftenvards the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.5 g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative.
- the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- 0.5 g of sodium hyaluronate ( 1.25 mmol, 15 kDa) were dissolved in 10 mL of demineralized water. Then, TEA (0.52 mL, 3 eq.) and DMAP (8 mg, 0.05 eq.) were added to the solution. Simultaneously, linoleic acid (0.77 mL, 2 eq.) was dissolved in 3 mL of THF and then TEA ( 1.2 mL, 7 eq.) and 2,4.6-trichlorobenzoyl chloride (0.391 mL, 2 eq.) were added to the solution. Following the activation of the acid, the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours and subsequently the reaction mixture was being warmed up at 50°C for 1 hour. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.75g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol. After having undergone decantation, the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85?/o by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- Example 15 Preparation of imolenyl (CI 8:3) derivative of hyaluronic acid by means of - the mixed anhydride of 2,4,6-trichlorobenzoic acid and linolenic acid
- 0.5 g of sodium hyaluronate ( 1.25 mmol, 15 kDa) were dissolved in 10 mL of demineralized water. Then. ⁇ (0.52 mL. 3 eq.) and DMAP (8 mg. 0.05 eq.) were added to the solution. Simultaneously, linolenic acid (0.765 mL, 2.0 eq.) was dissolved in 5 mL of THF and then TEA (0.52 mL. 3 eq.) and 2,4,6-trichlorobenzoyl chloride (0.391 mL, 2.0 eq.) were added to the solution. Following the activation of the acid, the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.75 g of NaCI.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4- fold of absolute isopropanol. After having undergone decantation, the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Aftenvards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- 0.5 g of sodium hyaluronate (1 .25 mmol. 1 5 kDa) were dissolved in 10 mL of demineralized water. Then, TEA (0.52 mL, 3 eq.) and DMAP (8 mg, 0.05 eq.) were added to the solution. Simultaneously, linolenic acid (0.382 mL. 1 eq.) was dissolved in 5 mL of THF and then TEA (0.52 mL. 3 eq.) and 2,4,6-trichlorobenzoyl chloride (0.195 mL, 1 eq.) were added to the solution.
- the precipitate was filtered into the prepared solution of HA.
- the reaction was taking place under room temperature for 3 hours and subsequently the reaction mixture was being warmed up at 50°C for 1 hour. Afterwards, the reaction mixture was diluted with 5 mL of demineralized water containing the addition of 0.25 g of NaCl.
- the acylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol.
- the precipitate was repeatedly washed initially with the aqueous solution of isopropanol (85% by vol.) in order to remove DMAP from the derivative and subsequently with absolute isopropanol in order to remove water from the derivative. Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours and subsequently it was lyophilized for the purpose of removing the residual solvents.
- Example 17 Encapsulation of tocopherol (vitamin E) into the capronyl (C6) derivative of hyaluronic acid
- the amount of bound tocopherol was: 2.3 % (w/w)
- Example 18 Encapsulation of Nile red into the capronyl (C6) derivative of hyaluronic acid
- the amount of bound Nile red (determined by means of the UV-Vis method) was: 0.4 %
- Example 19 Encapsulation of paclitaxel into the capronyl (C6) derivative of hyaluronic acid
- the amount of bound paclitaxel (determined by means of the HPLC method): 5 % (w/w)
- Example 20 Encapsulation of phosphatidylcholine into capronyl (C6) derivative of hyaluronic acid 100 mg of the acylated derivative of hyaluronan, which had been prepared according to Example 1. were being dissolved in 5 mL of water under continuous stirring for 3 hours. , The resulting solution was gradually (dropwise) supplemented with the solution of phosphatidylcholine ( 10 mg in 5 mL of EtOH) under continuous stirring. EtOH was removed from the solution in a continuous evaporation process. Subsequently, the residual aqueous phase was completely dried, rehydrated over an aqueous bath and filtered to an 1 ⁇ glass filter. The filtrate was lyophilized.
- C6 capronyl
- Example 21 Encapsulation of coenzyme Q10 into palmitoyl (CI 6) derivative of hyaluronic acid
- the amount of bound coenzyme Q 10 was: 12 % (w/w)
- Example 22 Encapsulation of tocopherol (vitamin E) into stearyl (C18) derivative of hyaluronic acid
- the amount of bound tocopherol was: 30 % (w/w)
- Example 23 Encapsulation of tocopherol (vitamin E) into oleyl (C18:l) derivative of hyaluronic acid
- the amount of bound tocopherol (determined by means of the UV-Vis method) was: 40 %
- Example 24 Encapsulation of coenzyme Q10 into palmitoyl (CI 6) derivative of hyaluronic acid
- the anrount of bound coenzyme Q10 was: 4.6 % (w/w)
- Example 25 Encapsulation of paclitaxel into the palmitoyl (C16) derivative of hyaluronic acid
- Example 26 Encapsulation of hop extract into oleyl (C18:l) derivative of hyaluronic acid
- the amount of bound tocopherol was: 40 % (w/vv)
- Example 27 Determination of the critical micellar (aggregation) concentrations of acylated derivatives of hyaluronic acid
- the critical micellar (aggregation) concentration was determined from the dependence of the fluorescence intensity on the solution concentrations ( Figure 1 ).
- micellar (aggregation) concentrations were determined: for HA C6: 0.001 -0.003 mg.mL "1 , for HA C I 6: 0.00006-0.0002 mg.mL/ 1 ( Figure 1 ). The same measurement value was obtained for PBS with the 0.9% NaCI solution.
- the critical micellar (aggregation) concentration was determined from the dependence of the intensities of scattered light (1 ⁇ 2) on the solution concentrations ( Figure 2).
- micellar (aggregation) concentrations were determined: for HA C6: 0.002-0.004 mg.mL "1 , for HA C 16: 0.00006-0,0001 mg.mL " ' ( Figure 2). The same measurement value was obtained for PBS with the 0.9% NaCI solution.
- Example 28 Determination of the zeta potential of hyaluronan nanomicelles
- the zeta potential was determined in the apparatus Zetasizer Nano-ZS (Malvern Instruments) equipped with a He-Ne laser (633 nm). Independently on the encapsulated substance, the zeta potential exhibited by the nanomicelles in aqueous solutions was— 50 - mV at 5 mg.mL " 1 and from ⁇ -60 to -70 mV after a 10-fold dilution. In the 0.9% solution of NaCI, the zeta potential range was reduced (-30 to -23 mV). Thus, the absolute value of the zeta potential indicates a high stability of the prepared nanomicelles in aqueous solutions and a relatively high stability of the same in salt solutions.
- Example 29 Morphological analysis of hyaluronan nanomicelles
- the microscopic analyses were carried out at - 135°C in the scanning microscope JEOL 740 I F working with the beam accelerating voltage of 2 kV (i.e. in a fine beam mode).
- 2-3 ⁇ L ⁇ of a concentrated sample (about 20 mg/0,4 mL) were dripped onto am Al plate and immersed into liquid nitrogen filled in the cryochamber Alta 2500 (Gatan). Subsequently, they were being coated with the Pt/Pd mixture for 2 minutes.
- Example 30 Distribution of acylated chains and nonpolar substances in hyaluronan nanomicelles
- the separation of the nanomicelles of hydrophobized hyaluronan with encapsulated vitamin E was carried out by means of the flow field-flow fractionation (F1FFF) method using a frit-inlet separation channel.
- F1FFF flow field-flow fractionation
- the separation took place under laboratory temperature.
- the eluate was monitored by - means of the light scattering detector DAWN EOS, the differential refractometer Optilab rEX (both made by the Wyatt Technology Corporation ) and the UV detector working with the wavelength of 292 nm (Shimadzu).
- Example 31 Cytotoxicity of nanomicelles carrying a paclitaxel based cytostatic drug
- a cultivating medium containing 10% of FBS
- NHDF-7 a cell line of human breast - carcinoma (MCF-7) and a cell line of human colon carcinoma (HCT 1 16) were used for testing the paclitaxel concentrations of 0.001 , 0.01 , 0.1 , 1 .0.
- the substances doxorubicin and 7-aminoactinomycin D (7-AAD, which is as substance that only penetrates into dead and permeabilized cells) were encapsulated into the acylated derivative of hyaluronan C6 in accordance with the procedure described in example 18 (where 7-AAD was substituted for Nile red).
- Cells of human dermal fibroblasts (NHDF), a cell line of human breast carcinoma (MCF-7) -and a cell line of human colon carcinoma (HCT 1 16) were used for testing the existence of a difference between the penetration of an substance into a cell when the substance is applied in a solution, in which it is present on its own) or in an acylated derivative of hyaluronan C6.
- the tests were carried out by means of the fluorescence microscopy method (inverted microscope Nikon Eclipse Ti). Doxorubicin was tested in the concentration of 5,0 ng/mL ( Figure 5) and 7-AAD was tested in the concentration of 15 ( Figure 6
- Example 33 Release of encapsulated oil red from nanomicelles into a solution
- oil red Oil Red O. solvent red 27
- HAC6 oil red encapsulated in HAC6 in accordance with the procedure described in example 18 (where Oil Red O was substituted for Nile red) into solutions was studied in vitro.
- the target solutions used were PBS and PBS with the addition of 1% of TWEEN 80.
- the aqueous solutions of acylated derivatives with bound oil red (in the concentration range between 1 and 10 mg.mL " 1 ) were dissolved in PBS or in PBS with the addition of 1% of TWEEN 80, quantitatively transferred into the dialysis tubing (MWCO 12- 14 kDa, Spectrum Laboratories) and dialysed under the temperature of 37 °C against PBS or against PBS with the addition of 1 % of TWEEN 80. In predefined time intervals. 4 mL of the dialysate were being sampled and replaced with a fresh medium. The released amount of oil red was determined by means of the UV-Vis method (Figure 7).
- the slow release of the bound substance is indicative of a high stability of carrier systems in PBS.
- Example 34 Release of encapsulated paclitaxel from nanomicelles into a solution
- Example 35 Preparation of nanoemulsions and microemulsions from the oleyl derivative (C18:l) of hyaluronic and oleic acids
- Particle size (determined in Zetasizer): 200-300 nm. The size was dependent on the amount of oil phase in the mixture.
- Example 36 Preparation of nanoemulsions and microemulsions from the oleyl derivative (C18:l) of hyaluronic and oleic acids with dissolved coenzyme Q10
- Particle size (determined in Zetasizer): 200-300 nm. The size was dependent on the amount of oil phase in the mixture.
- the reaction was taking place for 15 minutes. Afterwards, the activated acid was added to the hyaluronan solution and the reaction was taking place under the temperature of 25°C for 24 hours. The resulting reaction mixture was diluted with eater. The acrylated derivative was isolated from the reaction mixture in the subsequent precipitation process using the 4-fold of absolute isopropanol. After having undergone decantation, the precipitate was repeatedly washed with the aqueous solution of isopropanol (85% by vol.). Afterwards, the precipitate was being dried under the temperature of 40°C for 48 hours. The obtained acrylated derivative was acyiated (see example 1 ) and subsequently dissolved in water and lyophilized for the purpose of removing the residual solvents.
- the carrier system which had been prepared from oil red (Oil red O) and from the acrylated derivative according to Example 18 (where oil red was substituted for Nile red), was dissolved to form an 1% aqueous solution. In the resulting solution, the carrier system was cross-linked by means of ammonium peroxydisulfate ( 10 eq.) used as trigger.
- Example 38 Topical application of hyaluronan nanomicelles - penetration into skin, hairs and mucous membranes Swine skin, bovine vaginal mucous membrane and bovine buccal mucous membrane were donated by the company MasoEko, s.r.o.. based in Kuncice 243, Letohrad.
- the samples were subject to the passive action of the solution of acylated hyaluronan C6 and C I O ( 10 mg.mL " 1 ) with encapsulated Nile red (prepared in accordance with the procedure described in example 18) and the penetration into the samples was compared by measuring the fluorescence values in the inverted microscope Nikon Eclipse Ti (equipped with the objective lens Plan Fluor 4x).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Cosmetics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015012191A BR112015012191A8 (en) | 2012-11-27 | 2013-11-26 | acylated c6-c18 hyaluronic acid derivative, method of preparing a hyaluronic acid derivative, nanomicellar composition based on an acylated c6-c18 hyaluronic acid derivative, method of preparing nanomicellar composition, use of nanomicellar composition, stabilized nanomicellar composition |
KR1020157016788A KR102191353B1 (en) | 2012-11-27 | 2013-11-26 | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof |
EP13829034.1A EP2934592B1 (en) | 2012-11-27 | 2013-11-26 | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof |
RU2015125076A RU2640287C2 (en) | 2012-11-27 | 2013-11-26 | C6-c18-acylated derivative of hyaluronic acid, method for production nanomicellar composition based thereon, method for production and method for production of stabilized nanomicellar composition and its application |
JP2015543316A JP2016500130A (en) | 2012-11-27 | 2013-11-26 | C6-C18-acylated derivative of hyaluronic acid and process for its preparation, nanomicelle composition based on it and process for its preparation, process for preparing stabilized nanomicelle composition and use thereof |
DK13829034.1T DK2934592T3 (en) | 2012-11-27 | 2013-11-26 | C6-C18 acylated hyaluronic acid derivative, method of preparation thereof, on the basis of nanomicellar composition, method of preparation thereof, and method of preparation of a stabilized nanomicellar composition and use thereof |
US14/647,626 US9999678B2 (en) | 2012-11-27 | 2013-11-26 | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
PL13829034T PL2934592T3 (en) | 2012-11-27 | 2013-11-26 | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof |
ES13829034.1T ES2683993T3 (en) | 2012-11-27 | 2013-11-26 | C6-C18 acylated derivative of hyaluronic acid, its method of preparation, nanomicelar composition based on it, its method and preparation and method of preparation of the stabilized nanomicelar composition, and its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2012-842A CZ304654B6 (en) | 2012-11-27 | 2012-11-27 | C6-C18-acylated hyaluronate-based nanomicellar composition, process for preparing C6-C18-acylated hyaluronate, process for preparing nanomicellar composition and stabilized nanomicellar composition as well as use thereof |
CZPV2012-842 | 2012-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014082609A1 true WO2014082609A1 (en) | 2014-06-05 |
Family
ID=50097520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2013/000156 WO2014082609A1 (en) | 2012-11-27 | 2013-11-26 | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US9999678B2 (en) |
EP (1) | EP2934592B1 (en) |
JP (1) | JP2016500130A (en) |
KR (1) | KR102191353B1 (en) |
BR (1) | BR112015012191A8 (en) |
CZ (1) | CZ304654B6 (en) |
DK (1) | DK2934592T3 (en) |
ES (1) | ES2683993T3 (en) |
HU (1) | HUE038664T2 (en) |
PL (1) | PL2934592T3 (en) |
RU (1) | RU2640287C2 (en) |
WO (1) | WO2014082609A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016000669A3 (en) * | 2014-06-30 | 2016-02-25 | Contipro Pharma A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
WO2016141903A1 (en) * | 2015-03-09 | 2016-09-15 | Contipro Biotech S.R.O. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
WO2016194869A1 (en) * | 2015-05-29 | 2016-12-08 | 生化学工業株式会社 | Composition including glucosaminoglycan derivative and chemokine receptor activity regulator |
WO2017108015A1 (en) | 2015-12-23 | 2017-06-29 | Contipro A.S. | Fluorescent cypate conjugate of hyaluronic acid or salt thereof, hydrophobized conjugate, methods of perparation and use thereof |
US9999678B2 (en) | 2012-11-27 | 2018-06-19 | Contipro A.S. | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
WO2018113802A1 (en) | 2016-12-22 | 2018-06-28 | Contipro A.S. | Medical preparation with a carrier based on water insoluble hyaluronan conjugated to amino acids or peptides, method of preparation and use thereof |
US10023658B2 (en) | 2014-03-11 | 2018-07-17 | Contipro A.S. | Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof |
US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
WO2020002597A1 (en) | 2018-06-29 | 2020-01-02 | Merz Pharma Gmbh & Co. Kgaa | Fatty acid-grafted hyaluronic acid, dermal filler formulations comprising same, process for preparation and use thereof |
US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
FR3105922A1 (en) | 2020-01-08 | 2021-07-09 | Le Rouge Francais | Cosmetic composition for the treatment of the lips in the form of a compact solid containing at least one probiotic agent and at least one compound chosen from hyaluronic acid and its derivatives. |
CN114561827A (en) * | 2022-02-25 | 2022-05-31 | 华南理工大学 | Full-biomass-based wax emulsion waterproof coating and preparation method and application thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ307158B6 (en) * | 2016-12-23 | 2018-02-07 | Contipro A.S. | An ophthalmic preparation |
KR20220124207A (en) * | 2020-02-05 | 2022-09-13 | 아사히 가세이 가부시키가이샤 | Hyaluronic acid derivative composition, pharmaceutical composition and hyaluronic acid derivative-drug conjugate composition |
EP4101860A4 (en) * | 2020-02-07 | 2023-07-19 | Asahi Kasei Kabushiki Kaisha | Hyaluronic acid derivative, pharmaceutical composition, and hyaluronic acid derivative-drug conjugate |
KR102547183B1 (en) * | 2020-10-19 | 2023-06-26 | 주식회사 메피온 | Dermal filler and method for manufacturing the dermal filler |
CN112159527B (en) * | 2020-10-29 | 2023-06-06 | 绍兴文理学院 | Polyglycerol fatty acid ester HA-PG containing hyaluronic acid group, synthesis method thereof and application thereof in preparation of pharmaceutical preparation |
CN113476426B (en) * | 2021-06-29 | 2023-11-24 | 大连工业大学 | Preparation of hyaluronic acid-based dual-targeting functional factor delivery system and application of hyaluronic acid-based dual-targeting functional factor delivery system in inflammatory bowel disease |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720662A (en) | 1971-09-13 | 1973-03-13 | Nat Starch Chem Corp | Preparation of starch esters |
WO1996035720A1 (en) | 1995-05-10 | 1996-11-14 | Fidia Advanced Biopolymers S.R.L. | Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions |
EP0893451A2 (en) | 1997-07-25 | 1999-01-27 | National Starch and Chemical Investment Holding Corporation | Polysaccharide modification in densified fluid |
EP0941253A1 (en) | 1996-11-29 | 1999-09-15 | Societa' Cooperativa Centro Ricerche Poly-Tech a Responsabilita' Limitata | New butyric esters with antiproliferative activity and the pharmaceutical compositions containing them |
WO2004056877A1 (en) | 2002-12-23 | 2004-07-08 | Sintofarm S.P.A. | Mixed esters of hyaluronic acid with retinoic and butyric acids |
WO2005028632A2 (en) * | 2003-09-19 | 2005-03-31 | Colorado State University Research Foundation (Csurf) | Hyaluronan (ha) esterification via acylation technique for moldable devices |
EP1538166A1 (en) | 2003-12-04 | 2005-06-08 | Industrial Technology Research Institute | Biodegradable hyaluronic acid derivative and composition containing micelles made therefom |
WO2005092929A1 (en) | 2004-03-29 | 2005-10-06 | Sintofarm S.P.A. | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use |
WO2007033677A1 (en) | 2005-09-26 | 2007-03-29 | Novozymes Biopolymer A/S | Aryl/alkyl succinic anhydride hyaluronan derivatives |
CZ2006605A3 (en) | 2006-09-27 | 2008-04-09 | Cpn Spol. S R. O. | Polysaccharide modification process |
US7767806B2 (en) | 2003-09-08 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Hyaluronic acid modification products and drug carriers using them |
WO2010105582A1 (en) | 2009-03-17 | 2010-09-23 | Contipro C A.S. | A method of modification of hyaluronic acid by means of (o-acyl-o'-alkyl carbonate - substituted pyridine) complex |
CN101897976A (en) * | 2010-07-16 | 2010-12-01 | 沈阳药科大学 | Medicament solubilization carrier and preparation method and application thereof |
US20100316682A1 (en) | 2003-12-04 | 2010-12-16 | Industrial Technology Research Institute | Biodegradable Hyaluronic Acid Derivative, Biodegradable Polymeric Micelle Composition and Pharmaceutical or Bioactive Composition |
US20120172587A1 (en) | 2009-05-27 | 2012-07-05 | Frauhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Method for producing polysaccharide esters or polysaccharide mixed esters |
Family Cites Families (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3728223A (en) | 1971-10-08 | 1973-04-17 | Amano Pharma Co Ltd | Production of hyaluronidase from a strain of streptomyces |
GB1527592A (en) | 1974-08-05 | 1978-10-04 | Ici Ltd | Wound dressing |
CH628088A5 (en) | 1975-09-17 | 1982-02-15 | Dresden Arzneimittel | Process for obtaining streptococcal metabolic products |
US4205025A (en) | 1975-12-22 | 1980-05-27 | Champion International Corporation | Synthetic polymeric fibrids, fibrid products and process for their production |
JPS6033474B2 (en) | 1978-05-11 | 1985-08-02 | 藤沢薬品工業株式会社 | Novel hyaluronidase BMP-8231 and its production method |
US4716224A (en) | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
GB8519416D0 (en) | 1985-08-01 | 1985-09-04 | Unilever Plc | Oligosaccharides |
JPS62104579A (en) | 1985-10-30 | 1987-05-15 | Kyowa Hakko Kogyo Co Ltd | Production of hyaluronidase |
JPH0751064B2 (en) | 1986-08-13 | 1995-06-05 | 生化学工業株式会社 | Novel hyaluronidase SD-678 and method for producing the same |
IT1219587B (en) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
JPH0214019A (en) | 1988-06-30 | 1990-01-18 | Tonen Corp | Fibrous shaped material and production thereof |
JPH0755961B2 (en) | 1989-04-18 | 1995-06-14 | 工業技術院長 | Novel hyaluronic acid derivative and method for producing the same |
US5522879A (en) | 1991-11-12 | 1996-06-04 | Ethicon, Inc. | Piezoelectric biomedical device |
US5824335A (en) | 1991-12-18 | 1998-10-20 | Dorigatti; Franco | Non-woven fabric material comprising auto-crosslinked hyaluronic acid derivatives |
IT1254704B (en) | 1991-12-18 | 1995-10-09 | Mini Ricerca Scient Tecnolog | NON-WOVEN FABRIC ESSENTIALLY CONSTITUTED FROM DERIVATIVES OF HYALURONIC ACID |
JP2855307B2 (en) | 1992-02-05 | 1999-02-10 | 生化学工業株式会社 | Photoreactive glycosaminoglycans, cross-linked glycosaminoglycans and methods for producing them |
FR2689131B1 (en) | 1992-03-30 | 1994-05-20 | Oreal | PROCESS FOR THE PREPARATION OF MONOESTERS MAJORITY IN THE 6 'POSITION OF D-MALTOSE AND THEIR USE IN THE COSMETIC, ORAL-DENTAL, PHARMACEUTICAL AND FOOD FIELDS. |
JPH0625306A (en) * | 1992-04-21 | 1994-02-01 | Shiseido Co Ltd | Solvent-insoluble hyaluronic acid and its production |
IT1263316B (en) | 1993-02-12 | 1996-08-05 | Fidia Advanced Biopolymers Srl | MULTILAYER NON WOVEN FABRIC IN WHICH ONE OF THE LAYERS IS ESSENTIALS ESSENTIALS FROM HYALURONIC ACID ESTERS |
NL9700003A (en) | 1993-09-28 | 1997-07-01 | House Foods Corp | Method of inoculating Fistulina hepatica |
US5616568A (en) | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
HUT72406A (en) | 1994-03-14 | 1996-04-29 | Seikagaku Kogyo Co Ltd | Material to be worn on the eyeball |
US5455349A (en) | 1994-05-13 | 1995-10-03 | Polaroid Corporation | Vinylbenzyl thymine monomers |
DE69421943T2 (en) | 1994-09-27 | 2000-05-18 | Nycomed Imaging As | CONTRAST AGENTS |
US6025444A (en) | 1994-11-17 | 2000-02-15 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Cinnamic acid derivative |
JP3308742B2 (en) | 1994-11-17 | 2002-07-29 | 生化学工業株式会社 | Photocrosslinkable hyaluronic acid derivative, crosslinked product thereof and methods for producing them |
US5690961A (en) | 1994-12-22 | 1997-11-25 | Hercules Incorporated | Acidic polysaccharides crosslinked with polycarboxylic acids and their uses |
WO1996027615A1 (en) | 1995-03-07 | 1996-09-12 | Novartis Ag | Photochemically cross-linked polysaccharide derivatives as supports for the chromatographic separation of enantiomers |
KR100515314B1 (en) | 1995-08-29 | 2006-01-27 | 피디아어드밴스드바이오폴리머스에스.알.엘 | Biomaterials to prevent adhesion after surgery containing hyaluronic acid derivatives |
US5789462A (en) | 1995-09-13 | 1998-08-04 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Photocured crosslinked-hyaluronic acid contact lens |
DE19604706A1 (en) | 1996-02-09 | 1997-08-14 | Merck Patent Gmbh | Crosslinking products of biopolymers containing amino groups |
DE19616010C2 (en) | 1996-04-23 | 1998-07-09 | Seitz Filter Werke | Process and device for the production of fibrets (fibrids) from cellulose derivatives |
US6632802B2 (en) | 1996-08-29 | 2003-10-14 | Fidia Advanced Biopolymers S.R.L. | Hyaluronic acid esters, threads and biomaterials containing them, and their use in surgery |
IT1287698B1 (en) | 1996-08-29 | 1998-08-18 | Fidia Advanced Biopolymers Srl | SUTURE THREADS ESSENTIALLY MADE OF ESTERE DERIVATIVES OF HYALURONIC ACID |
WO1999001143A1 (en) | 1997-07-03 | 1999-01-14 | Orquest, Inc. | Cross-linked polysaccharide drug carrier |
BR9910574A (en) | 1998-04-30 | 2001-09-11 | Maruha Corp | Compounds derived from glycuronic acid and derived from glucosamine in their structure, method for the production of compounds, and use of compounds |
CN1141322C (en) | 1998-05-07 | 2004-03-10 | 荷兰应用科学研究会(Tno) | Process for elective oxidation of primary alcohols |
US6630457B1 (en) | 1998-09-18 | 2003-10-07 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
IT1302534B1 (en) | 1998-12-21 | 2000-09-05 | Fidia Advanced Biopolymers Srl | INJECTABLE, BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITIONS INCLUDING AT LEAST A DERIVATIVE OF HYALURONIC ACID, CHONDROGENIC CELLS, FOR |
ATE245452T1 (en) | 1998-12-23 | 2003-08-15 | Esparma Gmbh | HYALURONATE LYASE AS A PENETRATION PROMOTER IN TOPICAL AGENTS |
DE19917614C2 (en) | 1999-04-19 | 2001-07-05 | Thueringisches Inst Textil | Process for the production of cellulosic moldings with high adsorption capacity |
US6288043B1 (en) | 1999-06-18 | 2001-09-11 | Orquest, Inc. | Injectable hyaluronate-sulfated polysaccharide conjugates |
US6592794B1 (en) | 1999-09-28 | 2003-07-15 | Organogenesis Inc. | Process of making bioengineered collagen fibrils |
WO2001034657A1 (en) | 1999-11-08 | 2001-05-17 | Sca Hygiene Products Zeist B.V. | Process of oxidising primary alcohols |
DE10003397A1 (en) | 2000-01-27 | 2001-08-09 | Hartmann Paul Ag | Polyelectrolyte solid system, process for producing the same and wound dressing |
DE10009996B4 (en) * | 2000-03-02 | 2005-10-13 | Cognis Ip Management Gmbh | Solid granules with monodisperse particle size distribution, a process for their preparation and their use |
IT1317359B1 (en) | 2000-08-31 | 2003-06-16 | Fidia Advanced Biopolymers Srl | PERCARBOXYLATE POLYSACCHARIDES, SUCH AS HYALURONIC ACID, PROCESS FOR THEIR PREPARATION AND USE IN THE PHARMACEUTICAL FIELD AND |
IT1317358B1 (en) | 2000-08-31 | 2003-06-16 | Fidia Advanced Biopolymers Srl | CROSS-LINKATED DERIVATIVES OF HYALURONIC ACID. |
US6498269B1 (en) | 2000-10-17 | 2002-12-24 | The University Of Connecticut | Method for the oxidation of aldehydes, hemiacetals and primary alcohols |
AU2002219718A1 (en) | 2000-12-13 | 2002-06-24 | Sca Hygiene Products Zeist B.V. | Process for oxidising primary alcohols |
EP1217008B1 (en) | 2000-12-19 | 2006-03-01 | Seikagaku Corporation | Photocurable hyaluronic acid derivative and process for producing the same, and photocured crosslinked hyaluronic acid derivative and medical material using the same |
FR2819808B1 (en) | 2001-01-19 | 2003-04-18 | Simafex | STABILIZED COMPOSITIONS OF O-IODOXYBENZOIC ACID AND PROCESS FOR THEIR PREPARATION |
WO2002060971A1 (en) | 2001-01-31 | 2002-08-08 | Seikagaku Corporation | Crosslinked polysaccharide sponge |
US6902548B1 (en) | 2001-03-19 | 2005-06-07 | Ed Schuler | Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments |
US6673919B2 (en) | 2001-03-30 | 2004-01-06 | Chisso Cororation | Chemically modified hyaluronic acid or salts thereof, and a process for producing thereof |
US6946284B2 (en) | 2001-11-16 | 2005-09-20 | University Of Massachusetts | Solubilizing cross-linked polymers with photolyase |
US20060189516A1 (en) | 2002-02-19 | 2006-08-24 | Industrial Technology Research Institute | Method for producing cross-linked hyaluronic acid-protein bio-composites |
ITPD20020064A1 (en) | 2002-03-12 | 2003-09-12 | Fidia Advanced Biopolymers Srl | FOREIGN DERIVATIVES OF HYALURONIC ACID FOR THE PREPARATION OF HYDROGELD FOR USE IN THE BIOMEDICAL, SANITARY AND SURGICAL FIELD AND AS A SYSTEM |
JP3975267B2 (en) | 2002-06-03 | 2007-09-12 | 独立行政法人産業技術総合研究所 | Method for acylating polysaccharide substances |
US20040101546A1 (en) | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
JP4323148B2 (en) * | 2002-09-30 | 2009-09-02 | チッソ株式会社 | n-Alkanoylated hyaluronic acid or salt thereof and process for producing the same |
US7550136B2 (en) | 2002-12-20 | 2009-06-23 | University Of Massachusetts | Photo-reactive polymers and devices for use in hair treatments |
US7465766B2 (en) | 2004-01-08 | 2008-12-16 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US6982298B2 (en) | 2003-01-10 | 2006-01-03 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US20050126338A1 (en) * | 2003-02-24 | 2005-06-16 | Nanoproducts Corporation | Zinc comprising nanoparticles and related nanotechnology |
FR2852012B1 (en) | 2003-03-04 | 2006-06-23 | Oreal | PROCESS FOR THE PREPARATION OF O-ACYLATED GLUCOSE DERIVATIVES |
US7365059B2 (en) | 2003-03-11 | 2008-04-29 | Seikagaku Corporation | Photocrosslinked-polysaccharide composition and production process of the same |
ES2226567B1 (en) * | 2003-06-20 | 2006-07-01 | Universidad De Santiago De Compostela | NANOPARTICULAS OF HIALURONIC ACID. |
DE10331342B4 (en) | 2003-07-11 | 2009-03-12 | Thüringisches Institut für Textil- und Kunststoff-Forschung e.V. | Thermostable molding or spinning mass |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US7235295B2 (en) | 2003-09-10 | 2007-06-26 | Laurencin Cato T | Polymeric nanofibers for tissue engineering and drug delivery |
US20100330143A1 (en) | 2003-12-04 | 2010-12-30 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
WO2006010066A2 (en) | 2004-07-09 | 2006-01-26 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US7323425B2 (en) | 2004-08-27 | 2008-01-29 | Stony Brook Technology And Applied Research | Crosslinking of hyaluronan solutions and nanofiberous membranes made therefrom |
WO2006056204A1 (en) | 2004-11-24 | 2006-06-01 | Novozymes Biopolymer A/S | Method of cross-linking hyaluronic acid with divinylsulfone |
US7214759B2 (en) | 2004-11-24 | 2007-05-08 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
US7680038B1 (en) | 2005-04-25 | 2010-03-16 | Electronic Arts, Inc. | Dynamic bandwidth detection and response for online games |
GB0513552D0 (en) | 2005-07-01 | 2005-08-10 | Bristol Myers Squibb Co | Bandage |
CA2614312C (en) | 2005-07-06 | 2014-02-18 | Seikagaku Corporation | Drug-introduced photo-crosslinked hyaluronic acid derived gel |
ITPD20050206A1 (en) | 2005-07-07 | 2007-01-08 | Fidia Advanced Biopolymers Srl | BIOMATERIALS IN THE FORM OF FIBER TO BE USED AS MEDICAL DEVICES IN THE TREATMENT OF WOUNDS AND THEIR PROCESSES OF PRODUCTION |
ITMI20051415A1 (en) | 2005-07-22 | 2007-01-23 | Fidia Advanced Biopolymers Srl | BIOMATERIALS BASED ON SALT-MADE CORBOSSIMETHYLCELLULOSE WITH ZINC ASSOCIATED WITH IALURONIC ACID DERIVATIVES TO BE USED AS MEDICAL DEVICES WITH ANTIMICROBIAL AND ANTIFUNGAL ACTIVITY AND THEIR PRODUCTION PROCESS |
CN101282985B (en) | 2005-09-21 | 2013-07-10 | 科德生物工程有限公司 | Cell surface coating with hyaluronic acid oligomer derivative |
WO2007070617A1 (en) | 2005-12-14 | 2007-06-21 | Anika Therapeutics, Inc. | Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
EP1826274A1 (en) | 2006-02-24 | 2007-08-29 | Kikkoman Corporation | Enzyme composition, low molecular weight hyaluronan and process for preparing the same |
US20100273734A1 (en) | 2006-02-28 | 2010-10-28 | Novozymes Biopolymer A/S | Derivatives of Hyaluronic Acids |
DK1994062T3 (en) * | 2006-03-02 | 2009-11-16 | Novozymes Biopharma Dk As | Aryl / alkyl-vinylsulfonhyaluronsyrederivater |
JP4892679B2 (en) | 2006-03-27 | 2012-03-07 | 国立大学法人弘前大学 | Hyaluronic acid fiber by gel spinning and method for producing the same |
KR20070118730A (en) | 2006-06-13 | 2007-12-18 | 주식회사 코오롱 | Wound dressing materials with excellent ability to moisturized skin and method of manufacturing the same |
US20080124395A1 (en) | 2006-06-22 | 2008-05-29 | Weiliam Chen | Formulations and devices for treatment or prevention of neural ischemic damage |
JP2009545637A (en) | 2006-08-04 | 2009-12-24 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | Branched hyaluronic acid and method for producing the same |
US20080063617A1 (en) | 2006-09-07 | 2008-03-13 | Abrahams John M | Cosmetics formulations |
ITMI20061726A1 (en) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | CROSSLINKATI DERIVATIVES BASED ON HYALURONIC ACID RETICULATED VIA CLICK CHEMISTRY |
ATE545436T1 (en) | 2006-12-22 | 2012-03-15 | Croma Pharma Ges M B H | USE OF THIOLATED POLYSACCHARIDES FOR TISSUE BUILDING |
KR20080062092A (en) | 2006-12-29 | 2008-07-03 | 주식회사 핸슨바이오텍 | Hyaluronic acid derivatives for cell delivery carriers and their process for preparing the same |
EP1942117A1 (en) | 2006-12-29 | 2008-07-09 | Sigea S.R.L. | Derivatives of acid polysaccharides |
JP5329767B2 (en) | 2007-02-26 | 2013-10-30 | 帝人株式会社 | Aromatic copolyamide fiber production equipment |
WO2008115799A1 (en) | 2007-03-21 | 2008-09-25 | William Marsh Rice University | Novel gene delivery vectors for human mesenchymal stem cells |
CZ2007299A3 (en) | 2007-04-24 | 2009-02-04 | Cpn Spol. S R. O. | Preparation of nanofibers from polysaccharides and mixtures thereof with polyvinyl alcohol |
JP5165281B2 (en) | 2007-06-01 | 2013-03-21 | 株式会社バイオベルデ | Two-reactor type water-containing medical gel-forming agent and hyaluronic acid gel obtained therefrom |
WO2009037566A2 (en) | 2007-06-19 | 2009-03-26 | Uvarkina Tamara P | Hyaluronidase and method of use thereof |
EP2160484A2 (en) | 2007-06-22 | 2010-03-10 | Innovative Surface Technologies, Inc. | Nanofibers containing latent reactive groups |
US8268638B2 (en) | 2007-07-18 | 2012-09-18 | Advantageous Systems, Llc | Methods and apparatuses for detecting analytes in biological fluid of an animal |
FR2921675B1 (en) | 2007-09-28 | 2010-03-19 | Univ Claude Bernard Lyon | HYALURONIC ACID FILAMENT AND PROCESS FOR OBTAINING SAME |
US7976825B2 (en) | 2007-12-06 | 2011-07-12 | Janos Borbely | Cancer cell diagnosis by targeting delivery of nanodevices |
EP2242794B1 (en) | 2008-02-11 | 2014-04-30 | Basf Se | Method for producing porous structures from synthetic polymers |
EP3456749B1 (en) | 2008-02-29 | 2021-07-14 | PVAC Medical Technologies Ltd. | A substituted polyvinyl alcohol reagent |
JP5563563B2 (en) | 2008-06-05 | 2014-07-30 | エージェンシー フォー サイエンス, テクノロジー アンド リサーチ | Method for forming hydrogels in the presence of peroxidase and low concentrations of hydrogen peroxide |
JP2010014784A (en) | 2008-07-01 | 2010-01-21 | Fuji Xerox Co Ltd | Optical writing display apparatus, optical writing apparatus, and optical writing method |
FR2934999B1 (en) | 2008-08-13 | 2011-07-29 | Adocia | POLYSACCHARIDES FUNCTIONALIZED BY TRYPTOPHAN DERIVATIVES |
JP5722217B2 (en) | 2008-09-02 | 2015-05-20 | アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエAllergan Holdings France S.A.S. | Yarn of hyaluronic acid and / or its derivative, method for its preparation and use thereof |
CZ2008705A3 (en) | 2008-11-06 | 2010-04-14 | Cpn S. R. O. | Process for preparing DTPA crosslinked derivatives of hyaluronic acid and their modifications |
ITRM20080636A1 (en) | 2008-11-28 | 2010-05-29 | Univ Palermo | PROCEDURE FOR THE PRODUCTION OF FUNCTIONAL DERIVATIVES OF HYALURONIC ACID AND RELATIVE HYDROGELS. |
JP2010138276A (en) | 2008-12-11 | 2010-06-24 | Nipro Corp | Method for producing single yarn of hyaluronic acid |
US8648144B2 (en) | 2009-02-21 | 2014-02-11 | Sofradim Production | Crosslinked fibers and method of making same by extrusion |
WO2010095056A2 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Medical devices with an activated coating |
WO2010095052A2 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Compounds and medical devices activated with solvophobic linkers |
US8551378B2 (en) | 2009-03-24 | 2013-10-08 | North Carolina State University | Nanospinning of polymer fibers from sheared solutions |
US20120219554A2 (en) | 2009-05-14 | 2012-08-30 | Fidia Farmaceutici S.P.A. | Extracellular yaluronidase from streptomyces koganeiensis |
WO2010138074A1 (en) | 2009-05-29 | 2010-12-02 | Hilborn Joens | Hyaluronic acid based delivery systems |
JP2012529509A (en) * | 2009-06-09 | 2012-11-22 | ラックス・バイオサイエンシーズ・インコーポレイテッド | Topical drug delivery system for ophthalmic applications |
WO2011014432A1 (en) | 2009-07-30 | 2011-02-03 | Carbylan Biosurgery, Inc. | Modified hyaluronic acid polymer compositions and related methods |
KR101103423B1 (en) | 2009-09-04 | 2012-01-06 | 아주대학교산학협력단 | In situ forming hydrogel for tissue adhesives and biomedical use thereof |
US9132201B2 (en) | 2009-11-11 | 2015-09-15 | University Of Twente, Institute For Biomedical And Technical Medicine (Mira) | Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers |
WO2011059325A2 (en) | 2009-11-11 | 2011-05-19 | University Of Twente, Institute For Biomedical Technology And Technical Medicine (Mira) | Dextran-hyaluronic acid based hydrogels |
US20110111012A1 (en) | 2009-11-12 | 2011-05-12 | Hemcon Medical Technologies, Inc. | Nanomaterial wound dressing assembly |
CZ2009836A3 (en) | 2009-12-11 | 2011-06-22 | Contipro C A.S. | Hyaluronic acid derivative oxidized in position 6 of saccharide glucosamine portion selectively to aldehyde, process of its preparation and modification method thereof |
CZ302503B6 (en) | 2009-12-11 | 2011-06-22 | Contipro C A.S. | Process for preparing hyaluronic acid derivative oxidized in position 6 of polysaccharide glucosamine portion to aldehyde and modification process thereof |
US8197849B2 (en) | 2010-02-12 | 2012-06-12 | National Health Research Institutes | Cross-linked oxidated hyaluronic acid for use as a vitreous substitute |
CZ20101001A3 (en) | 2010-12-31 | 2012-02-08 | Cpn S.R.O. | Hyaluronic acid fibers, process of their preparation and use |
CZ304072B6 (en) | 2011-04-26 | 2013-09-25 | Contipro Biotech S.R.O. | Amphoteric material based on crosslinked hyaluronic acid, process for its preparation, materials containing active agents enclosed in hyaluronate network, process for their preparation and their use |
CN102154738B (en) | 2011-05-10 | 2012-08-01 | 青岛大学 | Method for preparing red algae agar fiber |
ITTO20110428A1 (en) | 2011-05-13 | 2012-11-14 | Rottapharm Spa | ESTERS OF HYALURONIC ACID, THEIR PREPARATION AND USE IN DERMATOLOGY |
KR101987120B1 (en) | 2011-10-18 | 2019-06-10 | 헤이큐 피티와이 엘티디 | Fibre-forming process and fibres produced by the process |
CZ2012282A3 (en) | 2012-04-25 | 2013-11-06 | Contipro Biotech S.R.O. | Crosslinked hyaluronate derivative, process of its preparation, hydrogel and microfibers based thereon |
CZ304512B6 (en) | 2012-08-08 | 2014-06-11 | Contipro Biotech S.R.O. | Hyaluronic acid derivative, process for its preparation, modification process and use thereof |
CZ2012841A3 (en) | 2012-11-27 | 2014-02-19 | Contipro Biotech S.R.O. | Fibers based on hydrophobized hyaluronate, process for their preparation and use, fabric based thereon and use thereof tp |
CZ304267B6 (en) | 2012-11-27 | 2014-02-05 | Contipro Biotech S.R.O. | Photoreactive derivative of hyaluronic acid, process for its preparation, 3D crosslinked derivative of hyaluronic acid, process for its preparation and use |
CZ304654B6 (en) | 2012-11-27 | 2014-08-20 | Contipro Biotech S.R.O. | C6-C18-acylated hyaluronate-based nanomicellar composition, process for preparing C6-C18-acylated hyaluronate, process for preparing nanomicellar composition and stabilized nanomicellar composition as well as use thereof |
CN103505736A (en) | 2013-09-23 | 2014-01-15 | 天津大学 | Modified hyaluronic acid based macromolecule lipidosome and preparation method thereof |
CZ305153B6 (en) | 2014-03-11 | 2015-05-20 | Contipro Biotech S.R.O. | Conjugates of hyaluronic acid oligomer or a salt thereof, process for their preparation and use |
-
2012
- 2012-11-27 CZ CZ2012-842A patent/CZ304654B6/en unknown
-
2013
- 2013-11-26 DK DK13829034.1T patent/DK2934592T3/en active
- 2013-11-26 KR KR1020157016788A patent/KR102191353B1/en active IP Right Grant
- 2013-11-26 PL PL13829034T patent/PL2934592T3/en unknown
- 2013-11-26 EP EP13829034.1A patent/EP2934592B1/en active Active
- 2013-11-26 ES ES13829034.1T patent/ES2683993T3/en active Active
- 2013-11-26 US US14/647,626 patent/US9999678B2/en active Active
- 2013-11-26 HU HUE13829034A patent/HUE038664T2/en unknown
- 2013-11-26 RU RU2015125076A patent/RU2640287C2/en active
- 2013-11-26 BR BR112015012191A patent/BR112015012191A8/en not_active Application Discontinuation
- 2013-11-26 JP JP2015543316A patent/JP2016500130A/en active Pending
- 2013-11-26 WO PCT/CZ2013/000156 patent/WO2014082609A1/en active Application Filing
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720662A (en) | 1971-09-13 | 1973-03-13 | Nat Starch Chem Corp | Preparation of starch esters |
WO1996035720A1 (en) | 1995-05-10 | 1996-11-14 | Fidia Advanced Biopolymers S.R.L. | Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions |
EP0941253A1 (en) | 1996-11-29 | 1999-09-15 | Societa' Cooperativa Centro Ricerche Poly-Tech a Responsabilita' Limitata | New butyric esters with antiproliferative activity and the pharmaceutical compositions containing them |
EP0893451A2 (en) | 1997-07-25 | 1999-01-27 | National Starch and Chemical Investment Holding Corporation | Polysaccharide modification in densified fluid |
WO2004056877A1 (en) | 2002-12-23 | 2004-07-08 | Sintofarm S.P.A. | Mixed esters of hyaluronic acid with retinoic and butyric acids |
US7767806B2 (en) | 2003-09-08 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Hyaluronic acid modification products and drug carriers using them |
WO2005028632A2 (en) * | 2003-09-19 | 2005-03-31 | Colorado State University Research Foundation (Csurf) | Hyaluronan (ha) esterification via acylation technique for moldable devices |
EP1538166A1 (en) | 2003-12-04 | 2005-06-08 | Industrial Technology Research Institute | Biodegradable hyaluronic acid derivative and composition containing micelles made therefom |
US20100316682A1 (en) | 2003-12-04 | 2010-12-16 | Industrial Technology Research Institute | Biodegradable Hyaluronic Acid Derivative, Biodegradable Polymeric Micelle Composition and Pharmaceutical or Bioactive Composition |
WO2005092929A1 (en) | 2004-03-29 | 2005-10-06 | Sintofarm S.P.A. | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use |
WO2007033677A1 (en) | 2005-09-26 | 2007-03-29 | Novozymes Biopolymer A/S | Aryl/alkyl succinic anhydride hyaluronan derivatives |
US7993678B2 (en) | 2005-09-26 | 2011-08-09 | Novozymes Biopolymer A/S | Hyaluronic acid derivatives |
CZ2006605A3 (en) | 2006-09-27 | 2008-04-09 | Cpn Spol. S R. O. | Polysaccharide modification process |
WO2010105582A1 (en) | 2009-03-17 | 2010-09-23 | Contipro C A.S. | A method of modification of hyaluronic acid by means of (o-acyl-o'-alkyl carbonate - substituted pyridine) complex |
US20120172587A1 (en) | 2009-05-27 | 2012-07-05 | Frauhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Method for producing polysaccharide esters or polysaccharide mixed esters |
CN101897976A (en) * | 2010-07-16 | 2010-12-01 | 沈阳药科大学 | Medicament solubilization carrier and preparation method and application thereof |
Non-Patent Citations (20)
Title |
---|
BOYER, 1. J.: "Toxicity of dibutyltin, tributyltin and other organotin compounds to humans and to experimental animals", TOXICOLOGY, vol. 55, no. 3, 1989, pages 253 - 298, XP025570955, DOI: doi:10.1016/0300-483X(89)90018-8 |
EENSCHOOTEN, C.; GUILLAUMIE, F.; KONTOGEORGIS, G. M.; STENBY, E. H.; SCHWACH-ABDELLAOUI, K.: "Preparation and structural characterisation of novel and versatile amphiphilic octenyl succinic anhydride-modified hyaluronic acid derivatives", CARBOHYDRATE POLYMERS, vol. 79, no. 3, 2010, pages 597 - 605, XP002722196, DOI: doi:10.1016/j.carbpol.2009.09.011 |
EENSCHOOTEN, C.; GUILLAUMIE, F.; KONTOGEORGIS, G. M.; STENBY, E. H.; SCHWACH-ABDELLAOUI, K.: "Preparation and structural characterisation of novel and versatile amphiphilic octenyl succinic anhydride-modified hyaluronic acid derivatives", CARBOHYDRATE POLYMERS, vol. 79, no. 3, 2010, pages 597 - 605, XP026806649 * |
GONG, J.; CHEN. M.; ZHENG, Y.; WANG, S.; WANG, Y.: "Polymeric micelles drug delivery system in oncology", JOURNAL OF CONTROLLED RELEASE, vol. 159, no. 3, 2012, pages 312 - 323, XP028482923, DOI: doi:10.1016/j.jconrel.2011.12.012 |
KEDAR, U.; PHUTANE, P.; SHIDHAYE, S.; KADAM, V.: "Advances in polymeric micelles for drug delivery and tumor targeting", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY AND MEDICINE, vol. 6, no. 6, 2010, pages 714 - 729, XP002722200, DOI: doi:10.1016/j.nano.2010.05.005 |
KEDAR, U.; PHUTANE, P.; SHIDHAYE, S.; KADAM, V.: "Advances in polymeric micelles for drug delivery and tumor targeting", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY AND MEDICINE, vol. 6, no. 6, 2010, pages 714 - 729, XP027547528 * |
KIM, T. G.; LEE, H.; JANG, Y.; PARK, T. G.: "Controlled Release of Paclitaxel from Heparinized Metal Stent Fabricated by Layer-by-Layer Assembly of Polylysine and Hyaluronic Acid-g-Poly(lactic-co-glycolic acid) Micelles Encapsulating Paclitaxel.", BIOMACROMOLECULES, vol. 10, no. 6, 2009, pages 1532 - 1539, XP055080317, DOI: doi:10.1021/bm900116r |
LAURA MAYOL ET AL: "Amphiphilic hyaluronic acid derivatives toward the design of micelles for the sustained delivery of hydrophobic drugs", CARBOHYDRATE POLYMERS, vol. 102, 1 February 2014 (2014-02-01), pages 110 - 116, XP055109658, ISSN: 0144-8617, DOI: 10.1016/j.carbpol.2013.11.003 * |
LI, J.; HUO, M.; WANG, J.; ZHOU, J.; MOHAMMAD, J. M.; ZHANG, Y.; ZHU, Q.; WADDAD, A. Y.; ZHANG, Q.: "Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel", BIOMATERIALS, vol. 33, no. 7, 2012, pages 2310 - 2320, XP028442480, DOI: doi:10.1016/j.biomaterials.2011.11.022 |
LIU, Y.; SUN, J.; CAO. W.; YANG, J.; LIAN, H.; LI, X.; SUN, Y.; WANG, Y.; WANG, S.; HE, Z.: "Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 421, no. 1, 2011, pages 160 - 169, XP028108693 * |
LIU, Y.; SUN, J.; CAO. W.; YANG, J.; LIAN, H.; LI, X.; SUN, Y.; WANG, Y.; WANG, S.; HE, Z.: "Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 421, no. 1, 2011, pages 160 - 169, XP028108693, DOI: doi:10.1016/j.ijpharm.2011.09.006 |
LNANAGA, J.; HIRATA, K.; SAEKI. H.; KATSUKI, T.; YAMAGUCHI, M.: "A Rapid Esterification by Means of Mixed Anhydride and Its Application to Large-ring Lactonization", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 52, no. 7, 1979, pages 1989 - 1993, XP001117758 * |
LNANAGA, J.; HIRATA, K.; SAEKI. H.; KATSUKI, T.; YAMAGUCHI, M.: "A Rapid Esterification by Means of Mixed Anhydride and Its Application to Large-ring Lactonization", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 52, no. 7, 1979, pages 1989 - 1993, XP002722199 |
MAZZONE, S. B.; MORI, N.; BURMAN, M.; PALOVICH, M.; BELMONTE, K. E.; CANNING, B. J.: "Fluorescent styryl dyes FM 1-43 and FM2-10 are muscarinic receptor antagonists: intravital visualization of receptor occupancy", THE JOURNAL OF PHYSIOLOGY, vol. 575, no. 1, 2006, pages 23 - 35 |
MEJKALOVÁ, D.; HERMANNOVA, M.; ULÁKOVÁ, R.; PR?OVÁ, A.; KUCERIK, J.; VELEBNÝ, V.: "Structural and conformational differences of acylated hyaluronan modified in protic and aprotic solvent system", CARBOHYDRATE POLYMERS, vol. 87, no. 2, 2012, pages 1460 - 1466, XP028112440, DOI: doi:10.1016/j.carbpol.2011.09.057 |
SHEN, Y.; LI, Q.; TU, J.; ZHU, J.: "Synthesis and characterization of low molecular weight hyaluronic acid-based cationic micelles fbr efficient siRNA delivery", CARBOHYDRATE POLYMERS, vol. 77, no. 1, 2009, pages 95 - 104, XP002722198 |
SHEN, Y.; LI, Q.; TU, J.; ZHU, J.: "Synthesis and characterization of low molecular weight hyaluronic acid-based cationic micelles fbr efficient siRNA delivery", CARBOHYDRATE POLYMERS, vol. 77, no. 1, 2009, pages 95 - 104, XP026019568 * |
TAO, Y.; XU, J.; CHEN, M.; BAI, H.; LIU, X.: "Core cross-linked hyaluronan- styrylpyridinium micelles as a novel carrier for paclitaxel", CARBOHYDRATE POLYMERS, vol. 88, no. 1, 2012, pages 118 - 124, XP028885586, DOI: doi:10.1016/j.carbpol.2011.11.075 |
TIT, H. P.; FALKE, H. E.; PRINSEN, M. K.; WILLEMS, M.1.: "Acute and subacute toxicity oftyramine, spermidine, spermine, putrescine and cadaverine in rats", FOOD AND CHEMICAL TOXICOLOGY, vol. 35, no. 3-4, 1997, pages 337 - 348, XP002398730, DOI: doi:10.1016/S0278-6915(97)00121-X |
WANG, J.; MONGAYT, D.; TORCHILIN, V. P.: "Polymeric micelles for delivery of poorly soluble drugs: Preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids", JOURNAL OF DRUG TARGETING, vol. 13, no. 1, 2005, pages 73 - 80, XP008126501, DOI: doi:10.1080/10611860400011935 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999678B2 (en) | 2012-11-27 | 2018-06-19 | Contipro A.S. | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
US10023658B2 (en) | 2014-03-11 | 2018-07-17 | Contipro A.S. | Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof |
JP2017519785A (en) * | 2014-06-30 | 2017-07-20 | コンティプロ アクチオヴァ スポレチノスト | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, its preparation and use |
WO2016000669A3 (en) * | 2014-06-30 | 2016-02-25 | Contipro Pharma A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
US10617711B2 (en) | 2014-06-30 | 2020-04-14 | Contipro A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
WO2016141903A1 (en) * | 2015-03-09 | 2016-09-15 | Contipro Biotech S.R.O. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
US10689464B2 (en) | 2015-03-09 | 2020-06-23 | Contipro A.S. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
WO2016194869A1 (en) * | 2015-05-29 | 2016-12-08 | 生化学工業株式会社 | Composition including glucosaminoglycan derivative and chemokine receptor activity regulator |
JPWO2016194869A1 (en) * | 2015-05-29 | 2018-03-22 | 生化学工業株式会社 | Composition comprising glycosaminoglycan derivative and chemokine receptor activity modulator |
US11253540B2 (en) | 2015-05-29 | 2022-02-22 | Seikagaku Corporation | Composition including glycosaminoglycan derivative and chemokine receptor activity regulator |
US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
WO2017108015A1 (en) | 2015-12-23 | 2017-06-29 | Contipro A.S. | Fluorescent cypate conjugate of hyaluronic acid or salt thereof, hydrophobized conjugate, methods of perparation and use thereof |
US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
WO2018113802A1 (en) | 2016-12-22 | 2018-06-28 | Contipro A.S. | Medical preparation with a carrier based on water insoluble hyaluronan conjugated to amino acids or peptides, method of preparation and use thereof |
WO2020002597A1 (en) | 2018-06-29 | 2020-01-02 | Merz Pharma Gmbh & Co. Kgaa | Fatty acid-grafted hyaluronic acid, dermal filler formulations comprising same, process for preparation and use thereof |
FR3105922A1 (en) | 2020-01-08 | 2021-07-09 | Le Rouge Francais | Cosmetic composition for the treatment of the lips in the form of a compact solid containing at least one probiotic agent and at least one compound chosen from hyaluronic acid and its derivatives. |
CN114561827A (en) * | 2022-02-25 | 2022-05-31 | 华南理工大学 | Full-biomass-based wax emulsion waterproof coating and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
RU2015125076A (en) | 2017-01-13 |
CZ2012842A3 (en) | 2014-08-20 |
HUE038664T2 (en) | 2018-11-28 |
KR102191353B1 (en) | 2020-12-16 |
US20150320873A1 (en) | 2015-11-12 |
EP2934592A1 (en) | 2015-10-28 |
BR112015012191A8 (en) | 2018-01-23 |
KR20150088848A (en) | 2015-08-03 |
ES2683993T3 (en) | 2018-10-01 |
RU2640287C2 (en) | 2017-12-27 |
JP2016500130A (en) | 2016-01-07 |
DK2934592T3 (en) | 2018-07-02 |
US9999678B2 (en) | 2018-06-19 |
BR112015012191A2 (en) | 2017-07-11 |
PL2934592T3 (en) | 2018-12-31 |
CZ304654B6 (en) | 2014-08-20 |
EP2934592B1 (en) | 2018-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2934592B1 (en) | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof | |
Zhang et al. | Enzyme and redox dual-triggered intracellular release from actively targeted polymeric micelles | |
Nosrati et al. | Folic acid conjugated bovine serum albumin: An efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells | |
Jia et al. | Multi-functionalized hyaluronic acid nanogels crosslinked with carbon dots as dual receptor-mediated targeting tumor theranostics | |
Li et al. | Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel | |
Zhang et al. | A facile approach for dual-responsive prodrug nanogels based on dendritic polyglycerols with minimal leaching | |
Wang et al. | Engineering multifunctional bioactive citric acid-based nanovectors for intrinsical targeted tumor imaging and specific siRNA gene delivery in vitro/in vivo | |
Li et al. | Self-assembled chlorin e6 conjugated chondroitin sulfate nanodrug for photodynamic therapy | |
Lee et al. | Endolysosomal environment-responsive photodynamic nanocarrier to enhance cytosolic drug delivery via photosensitizer-mediated membrane disruption | |
Liu et al. | Novel pH-sensitive chitosan-derived micelles loaded with paclitaxel | |
Kumar et al. | Lipophilic 5-fluorouracil prodrug encapsulated xylan-stearic acid conjugates nanoparticles for colon cancer therapy | |
Tian et al. | The effect of the molecular weight of hyaluronic acid on the physicochemical characterization of hyaluronic acid-curcumin conjugates and in vitro evaluation in glioma cells | |
Ji et al. | Multistimulative nanogels with enhanced thermosensitivity for intracellular therapeutic delivery | |
Cao et al. | Folate-conjugated polyphosphoester with reversible cross-linkage and reduction sensitivity for drug delivery | |
Hu et al. | Core cross-linked polyphosphoester micelles with folate-targeted and acid-cleavable features for pH-triggered drug delivery | |
Deng et al. | Hydrophobic IR780 loaded sericin nanomicelles for phototherapy with enhanced antitumor efficiency | |
Shirani et al. | Redox responsive polymeric micelles of gellan gum/abietic acid for targeted delivery of ribociclib | |
Xu et al. | Reduction and pH dual-responsive nanoparticles based chitooligosaccharide-based graft copolymer for doxorubicin delivery | |
Xu et al. | Synthesis and in vitro evaluation of a hyaluronic acid–quantum dots–melphalan conjugate | |
Li et al. | Tailored Trojan horse nanocarriers for enhanced redox-responsive drug delivery | |
You et al. | Amphiphilically modified chitosan cationic nanoparticles for drug delivery | |
Jang et al. | π-Hyaluronan nanocarriers for CD44-targeted and pH-boosted aromatic drug delivery | |
Liu et al. | pH-Sensitive Dextran-Based Micelles from Copper-Free Click Reaction for Antitumor Drug Delivery | |
Grant et al. | Influence of molecular organization and interactions on drug release for an injectable polymer-lipid blend | |
Wang et al. | Facile One‐Pot Synthesis of Self‐Assembled Folate‐Biotin‐Pullulan Nanoparticles for Targeted Intracellular Anticancer Drug Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13829034 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015543316 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14647626 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015012191 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013829034 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157016788 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015125076 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015012191 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150526 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112015012191 Country of ref document: BR Kind code of ref document: A8 Free format text: EXPLIQUE A DIVERGENCIA NO NOME DE UM DOS INVENTORES ( GLORIA HUERTA-ANGELES) QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2014/082609 E O CONSTANTE DA PETICAO INICIAL NO 860150103766 . |
|
ENP | Entry into the national phase |
Ref document number: 112015012191 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150526 |